You are viewing the site in preview mode

Skip to main content

Advertisement

Table 1 patient characteristics(n = 751)

From: Analysis of definitive chemo-radiotherapy for esophageal cancer with supra-clavicular node metastasis based on CT in a single institutional retrospective study: a propensity score matching analysis

Characteristic SCLN status SCLN status(after matching)
Negative (n = 596) Positive (n = 155) P value Negative (n = 140) Positive (n = 140) P value
Age (years) ≤65 years 306(51.3%) 99(63.9%) 0.063 90(64.3%) 85(60.7%) 0.537
> 65 years 290(48.7%) 56(36.1%) 50(35.7%) 55(39.3%)
Sex Male 432(72.5%) 121(78.1%) 0.348 104(74.3%) 108(77.1%) 0.577
Female 164(27.5%) 34(21.9%) 36(25.7%) 32(22.9%)
Histology SCC 567(95.1%) 143(92.3%) 0.390 134(95.7%) 130(92.9%) 0.352
Others 29(4.9%) 12(7.7%) 6(4.3%) 10(7.1%)
Tumor length ≤5 cm 207(34.7%) 32(20.6%) 0.027 30(21.4%) 30(21.4%) 1.000
> 5 cm 389(65.3%) 123(79.4%) 110(78.6%) 110(78.6%)
Tumor diameter ≤3 cm 210(35.2%) 34(21.9%) 0.042 37(26.4%) 30(21.4%) 0.327
> 3 cm 386(64.8%) 121(78.1%) 103(73.6%) 110(78.6%)
T stage T1/T2 190(31.9%) 29(18.7%) 0.002 27(19.3%) 27(19.3%) 0.175
T3 174(29.2%) 27(17.4%) 39(27.9%) 24(17.1%)
T4 232(38.9%) 99(63.9%) 74(52.9%) 89(63.6%)
N stage N0 158(26.5%) 0(0%) 0.000 17(12.1%) 0(0.0%) 0.180
N1 312(52.3%) 33(21.3%) 24(17.1%) 33(23.6%)
N2 111(18.6%) 92(59.4%) 84(60.0%) 88(62.9%)
N3 15(2.5%) 30(19.4%) 15(10.7%) 19(13.6%)
Chemotherapy Yes 384(64.4%) 129(83.2%) 0.002 32(22.9%) 26(18.6%) 0.376
No 212(35.6%) 26(16.8%) 108(77.1%) 114(81.4%)
Tumor location Cervical 37(6.2%) 9(5.8%) 0.869 6(4.3%) 9(6.4%) 0.792
Upper 121(20.3%) 36(23.2%) 35(25.0%) 32(22.9%)
Middle 332(55.7%) 88(56.8%) 78(55.7%) 80(57.1%)
Lower 106(17.8%) 22(14.2%) 21(15.0%) 19(13.5%)
number of LN 0 160(26.8%) 0(0.0%) 0.000 17(12.1%) 0(0.0%) 0.137
1–2 310(52.0%) 34(21.9%) 24(17.1%) 34(24.3%)
> 3 126(21.1%) 121(78.1%) 99(70.7%) 106(75.7%)